The Future of Radioligand Therapy: α, β, or Both?
Abstract
Endoradiotherapy approaches are experiencing growing interest with the increase in the number of carrier molecules becoming available for different targets. The cross-fire effect has been described as an important mechanism for the efficacy of radioligand therapies by particle-induced destruction of
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Due to the range of β particles, emitted β particles traverse several cells (10-1000), an effect termed 'cross-fire effect' that is responsible for possible destruction of multiple cells in the vicinity of the tracer-accumulating cell.
“Due to the range of the β particles in comparison to the diameter of a cell, the emitted β particles traverse several cells (10–1000) [30]. This effect has been termed “cross-fire effect” and is responsible for the possible destruction of multiple cells in the vicinity of the tracer-accumulating cell [31].”
From Lutathera®: The First FDA- and EMA-Approved Radiopharmaceutical for Peptide Receptor Radionuclide Therapy (2019) · cites this paper as [31]
A radiation-induced bystander effect occurs: cells not directly exposed to ionizing radiation but in the neighborhood of such cells behave as if they have been directly hit.
“Another therapeutic effect is the radiation-induced bystander effect: Cells that have not been directly exposed to ionizing radiation, but are in the neighborhood of such cells, behave as if they have been directly hit [31].”
From Lutathera®: The First FDA- and EMA-Approved Radiopharmaceutical for Peptide Receptor Radionuclide Therapy (2019) · cites this paper as [31]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
The citation lists haven’t been fetched yet
References 13 · Cited by 88
- Authors
- Haberkorn, U., Giesel, F., Morgenstern, A., & Kratochwil, C.
- Affiliations
- German Cancer Research Center (DE)
- University Hospital Heidelberg (DE)
- European Commission (BE)
- Venue
- Journal of Nuclear Medicine
- Publisher
- Society of Nuclear Medicine
- Published
- 2017-04-13
- Volume
- 58
- Issue
- 7
- Pages
- 1017-1018
- ISSN
- 0161-5505 (ISSN-L)
- 2159-662X
- OpenAlex
- W2606353760
- Cited by
- 88
- References
- 13
- Citations by year
- 2026: 10 · 2025: 14 · 2024: 11 · 2023: 12 · 2022: 16 · 2021: 3 · 2020: 14 · 2019: 2 · 2018: 6
- FWCI
- 4.55
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Journal of Nuclear Medicine (publishedVersion)
- PubMed (publishedVersion)
- Joint Research Centre (European Commission) (submittedVersion)
- Topics
- Health Sciences › Medicine › Radiology, Nuclear Medicine and Imaging › Radiopharmaceutical Chemistry and Applications
- Health Sciences › Medicine › Radiology, Nuclear Medicine and Imaging › Medical Imaging Techniques and Applications
- Health Sciences › Medicine › Epidemiology › Neuroendocrine Tumor Research Advances
- Keywords
- radioligand therapy, endoradiotherapy, alpha-emitting radionuclides, beta emitters, carrier molecules, targeted radionuclide therapy
- MeSH terms
- Alpha Particles, Beta Particles, Humans, Ligands, Neoplasms, Positron-Emission Tomography
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
